SMILE

Patient <u>Safety Monitoring in International Laboratories</u>

Our Mission:

To Provide Quality Assurance Support for DAIDS-Funded HIV Clinical Trial Laboratories (Non-US)

To Maintain a Web-Based Repository of Records and Resources

Mark Swartz, MT(ASCP) Anne Sholander, MT(ASCP) International QA/QC Coordinators, SMILE

ACKNOWLEDGEMENTS



This project has been funded in whole or in part with Federal funds from the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract No. HHSN266200500001C, titled Patient Safety Monitoring in International Laboratories.



Johns Hopkins University – SMILE Staff Dr. Robert Miller - Principal Investigator Barbara Parsons - Operations Manager Kurt Michael - Project Manager

Who is SMILE?

- Contract resource between NIH/NIAID-DAIDS & Johns Hopkins University
- Staff of 12 with a wide range of laboratory experience



Major Functions of SMILE

Action Plans

- Validation Review
- Protocol Analyte Lists
 - EQA Review
 - Investigations
 - Resources/Training



Who are the partners?



Laboratory Audits

Independent assessments are performed annually by PPD or DAIDS



Based on the standards of Good Clinical Laboratory Practice (GCLP)

Clinical Research Support Contract No. N01-AI-50022

This project has been funded in whole or in part with Federal funds from the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract No. N01-AI-50022, titled HIV Clinical Research Support (CRS) Services.

	Laboratory Audit Vi	sit of
c	onducted by PPD Laborate	orv Services
		-
	Final Report Issued: 08 Sept	-
©2008	Pharmaceutical Product Development,	Inc. All rights reserved.
To be completed on PPD Si		Date:
Audited By:(Print Nat	ne)	

- Ordered by the DAIDS POC for your site
- Pre-visit checklist sent about 2 weeks before audit

IX. Test and Control Articles, continued

C. QC Materials

Comments:

 QC materials were not dated with new expiration dates after opening or reconstitution; however, materials were labeled with the opened or preparation dates, and the stability of the materials was documented in the written procedures.

D.	Calibration Materials			
1.	Are calibration materials utilized by the laboratory? (If "No", skip to Section E.)	Yes 🛛	No 🗌	Comments 🗌
2.	Are all calibration materials dated within the manufacturer's assigned expiration dates?	Yes 🛛	No 🗌	Comments 🗌
3.	Are all calibration materials properly stored, as required by the manufacturer?	Yes 🛛	No 🗌	Comments 🗌
4.	Are all calibration materials properly labeled to indicate identity, lot number, storage requirement, date prepared/reconstituted, and expiration date?	Yes 🗆	No 🖂	Comments 🛛

Comments:

4.

Calibration materials were not dated with new expiration dates after opening or reconstitution; however, materials were labeled with the opened or preparation dates, and the stability of the materials was documented in the written procedures.

Ε.	Reagent/Testing Kits			
1.	Are all reagent/testing kits dated within the manufacturer's assigned expiration dates?	Yes 🛛	No 🗌	Comments 🗌
2.	Are all reagents/testing kits properly stored, as described by the manufacturer?	Yes 🛛	No 🗌	Comments 🗌
3.	Are all reagents/solutions properly labeled to indicate identity, lot number, storage requirement, date prepared/reconstituted, and expiration date?	Yes 🗌	No 🛛	Comments 🛛

Comments:

 Hematology reagents were not labeled with the new expiration dates after opening; however, the reagents were consumed well within the expiry dates, according to the Hematology Coordinator, Agda Moraes.


Audits and Action Plans


- 1. Audit report sent to SMILE
- 2. Action Plan is prepared
- 3. SMILE returns the AP to DAIDS POC for distribution to the affiliated networks
- 4. Networks designate critical items
- Action Plan and audit report sent to lab by DAIDS POC

		111	▼ (* <i>f</i> x						
	Α	В	С	D	E	F	G		
1	_		Кеу						
-		mplete				Brazil			
3	In F	Progress			HPTN, IMPA				
4	Sta	tus Unknown		SMILE comments in BLUE.					
5	Contingent or Critical Items			Site comments in RED.	PPD Audit Visit 15-21 L				
	Acti	ion Recommend	led; Follow-up Not Expected		Revised: 20 September 2011				
Ť					rtevised. 20 September 201		STATUS &		
7		Audit SUB- SECTION OBSERVATION / FINDING		SUGGESTED ACTION	HISTORY	REVIEWER COMMENTS	DATE		
8				SECTION II- ORGANIZATION AND I	PERSONNEL				
			Organization chart						
9	1	II. A	a section specific organizational chart was not available for the Chemistry department. The job titles on the organizational charts were not consistent with the job titles listed in personnel records.	Create a section specific organogram for the Chemistry department. Review the organograms in all departments to ensure that the job titles listed on the organograms are consistent with the job descriptions in personnel records. Submit updated organograms to SMILE for review.	09 Mar 11: Chemistry Organogram received. Revised organograms for Serology, Hematology and Flow Cytometry received. (AS)		14-Mar-11		
10	2	II. B. 1-8 XIII. A. 1, 5	Availability of personnel records the auditor noted that personnel records were not available for review because they were stored off site and the administrative office required one week's advance notice for retrieving the files.	For future audits, please make sure that all required records are available for review by the auditor. The pre-audit checklist should serve as a reminder to request all personnel records in advance. Notify SMILE when complete.					
11	3	II. B. 1	Personnel records no personnel file was maintained for the Section Coordinator in Serology. One Medical Coordinator personnel file contained no records.	Create a personnel file for the Section Coordinator in Serology. Update the personnel file for the Medical Coordinator with the appropriate records. Notify SMILE when complete.					
12	4	II. B. 2	Job descriptions two job descriptions had not been signed (laboratory technicians in Flow Cytometry and Chemistry).	Ensure that the two job descriptions cited have been signed by the appropriate personnel. Notify SMILE when complete.	20 Sept 11: signed job descriptions submitted to SMILE. (AS)		20-Sep-11		
13	5	II. B. 3	Position profiles there was no job profile for the QA/QC Unit position.	Update the listing of position profiles to include the educational and experience requirements for the QA/QC Unit position. Submit the updated list to SMILE when complete.	31 Aug 11: Updated position profiles received. (AS)		31-Aug-11		
14	6	II. B. 5	Assay specific training records training provided by the manufacturers was not documented in personnel files. Ortho provided training certificates by the end of the audit. Training for the Sysmex analyzer was not documented. Competency records- on Plan Template	Ensure that training certificates are obtained from manufacturers performing assay specific training. Document all training in the appropriate personnel files. Notify SMILE when the Sysmex training certificate is received.	0.4 Ave- 44. The				
		- AGGIC ACU							
Red	eady								

Validation Review and Assistance

- Common findings from PPD audits
- New protocols/new tests
- New instrumentation
- Request from networks
- Lab moving





Types of validation resources

- Total Allowable Error (TEa) limits table
- Validation Overviews
- Detailed validation guidelines/instructions
 - Chemistry, Hematology, HIV EIA, Rapid HIV, Viral Markers EIA, Coagulation
- Statistical calculation tools
- Plan and Summary templates for each type of assay

What are we looking for??

- Precision
- Accuracy
- Linearity (Analytical Measurement Range + Clinical Reportable Range)
- Sensitivity and Specificity
- Reference Ranges

SMILE Johns Hopkins University

Quantitative Validation Overview


Validation of a quantitative system (for example Chemistry analyzer or Hematology analyzer) consists of an established set of required experiments. Each laboratory should first design a validation plan describing how they will satisfy each of these requirements. The validation plan must also detail the acceptability criteria for each element. After completing all of the validation experiments, results should be compiled and filed in an organized manner. All validation records should be retained for the life of the instrument. A validation summary should be prepared that contains a place for the Laboratory Director to sign, indicating the validation has been reviewed and approved.

The following are the required components of validation:

- Precision is reproducibility the agreement of the measurements of replicate runs of the same sample. Replication experiments are performed to estimate the imprecision or random error of the analytical method. See SMILE Precision Guidelines.
- Accuracy is the true value of a substance being measured. Verification of accuracy
 is the process of determining that the test system is producing true, valid results.
 See SMILE Accuracy Guidelines.
- 3. Linearity A quantitative analytical method is said to be linear when measured results from a series of sample solutions are directly proportional to the concentration or activity in the test specimens. This means that a straight line can be used to characterize the relationship between measured results and the concentrations or activity levels of an analytefor a determined range of analyte values. See SMILE Linearity Guidelines.
- 4. The Analytical Measurement Range (AMR) is the range of analyte values that a method can directly measure on the specimen without any dilution, concentration, or other pretreatment not part of the usual assay process. AMR validation is the process of confirming that the assay system will correctly recover the concentration or activity of the analyte over the AMR. The manufacturer defines the AMR but it is the laboratory's responsibility to verify it. See SMILE AMR and CRR Guidelines.
- 5. The Clinical Reportable Range (CRR) is the range of analyte values that a method can report as a quantitative result, allowing for specimen dilution, concentration or other pretreatment used to extend the AMR. The laboratory should establish a CRR that covers the range of a Grade 4 Adverse Event on the DAIDS Toxicity Table

For each of the required elements...

- Minimum number of samples tested
- Appropriate samples selected
- Comparison to a previously validated method
- Evaluation criteria clearly stated
- Evidence of comparison to manufacturer's specifications
- Raw data that supports conclusions



What is an auditor looking for??



- All of the above PLUS...
- All data summarized in an easy-to-understand, organized report
- Raw data that supports the conclusions
- LABORATORY DIRECTOR SIGNATURE

Insert Lab Header here Include full name and address of Lab

Validation Summary Report

Purpose: □Validation □Re-Validation □Other:

Description of Equipment/Process:

Equipment/Process: Insert full name of analyzer (ex: Cobas Integra 400+)

Serial Number: Insert instrument serial number

Location: Insert name of lab, city, state and country

Date: Insert date range of validation studies

FDA Approval Status:
Approved
Not approved

Procedure:

Refer to the insert lab name Validation Plan for insert instrument name Ex: Refer to the XYZ Lab Validation plan for Cobas Integra 400

Results: All raw data reports and statistical analysis can be found in the <u>insert</u> instrument name Validation binder.

1. Precision-refer to tab A

	Expected	Posults	Observed	Results	
Analyte	Expected	Results	Betweer	Acceptability	
, unary to	Manufacturer's Precision	33% of CLIA	Normal Control CV%	Abn Control CV%	receptuonity
EX:ALT	3.3% 6.6%		3.8%	4.3%	Acceptable






Reference Range Approval									
Medical Director:		Date:							
	Insert Medical director name here								
Method Approval									
Approved / Not Ap	Approved / Not Approved								
If not approved, p	If not approved, provide recommendations/corrective actions below.								
Laboratory Directo	Dr:	Date:							
Insert Lab director name here									
Prepared by:	Insert name and title here	_Date:							

Protocol Analyte List (PAL)

- Protocol analytes
- Instrumentation in use
- FDA Approval status
- Back-up plans
- Specimen flow



	A		<u> </u>	U	L .					J	K	L	р	
1		La	aboratory Nam	e: 7 CLINICAL	. TRIALS O			ROUTINE LAB	& ABC/QR	S DURBAN	& JHB			-
2						Protoco	DI: MTN003				Completed By:			
4											Date Completed:	3-May-11		
5														
6	Assay		Primary Instrument		as much detail		<i>can provide. Please s</i> ary Method/Reage	add any assays that are	missing.					
7	nssay				EDA				EDA	D:	E . 104	-	504 D 1	
8		Instrument Name	Instrument Manufacturer	Instrument Model Number	FDA Approved (Yes/No/D on't Knov)	Method/Kit Name	Method/Kit Manufacturer	Method/Kit Product Number or Product Code	FDA Approved (Yes/No/D on't Knov)	Primary laboratory performing testing for this	External QA provider	Frequenc y of EQA	EQA Panel Details	1
9	<u>Chemistry</u>													A I
_10	ALT (SGPT)	COBAS INTEGRA	ROCHE	400 PLUS	FDA/CE	(IFCC), without pyridoxal-5'- phosphate	ROCHE	20764957	FDA/CE	ABC Lab JHB	CAP & THISTLE	3 per yr / 1 every two wks	CAP C3 X 5 MEMBER	
11	AST (SGOT)	COBAS INTEGRA	ROCHE	400 PLUS	FDACE	(IFCC), without pyridoxal-5'- phosphate	ROCHE	20764949	FDA/CE	ABC Lab JHB	CAP & THISTLE	3 per yr / 1 every two wks	CAP C3 X 5 MEMBER	
12	Phosphate (inorganic)	COBAS INTEGRA	ROCHE	400 PLUS	FDA/CE	Phosphomolybdat e UV /Integra 400plus / Roche	ROCHE	3183793	FDA/CE	ABC Lab JHB	CAP & THISTLE	3 per yr / 1 every two wks	CAP C3 X 5 MEMBER	
13	Creatinine	COBAS INTEGRA	ROCHE	400 PLUS	FDA/CE	Jaffé Compensated	ROCHE	20764345	FDA/CE	ABC Lab JHB	CAP & THISTLE	3 per yr / 1 every two wks	CAP C3 X 5 MEMBER	
14	<u>Urinalysis</u>													
15	Dipstick Urinalysis	N/A	N/A	N/A	N/A	Multi-stix 9, Uristix 4 and 2	Siemens	N/A	YES	XYZ Clinics	CAP	Twice Annually	СММ	
16	Urine β-hCG	N/A	N/A	N/A	N/A	Quidel Quickvue	Quidel	BMX/97016	YES	XYZ Clinics	CAP	Twice Annually	СММ	
17	<u>Hematology</u>													A 1
18	Hemoglobin	COULTER	BECKMAN COULTER	LH 750	FDA/CE	Coulter	BECKMAN COULTER	NA	FDA/CE	ABC Lab JHB	CAP	3 per yr	FH 6	
19	Hematocrit	COULTER	BECKMAN COULTER	LH 750	FDA/CE	calculation	BECKMAN COULTER	NA	FDA/CE	ABC Lab JHB	CAP	3 per yr	FH 6	Ļ
20	White Blood Cell (WBC) Count	COULTER	BECKMAN COULTER	LH 750	FDA/CE	Coulter principle	BECKMAN COULTER	NA	FDA/CE	ABC Lab JHB	CAP	3 per yr	FH 6	Ļ
21	Red Blood Cell (RBC) Count	COULTER	BECKMAN COULTER	LH 750	FDA/CE	Coulter principle	BECKMAN COULTER	NA	FDA/CE	ABC Lab JHB	CAP	3 per yr	FH 6	Ļ
22	Platelet Count	COULTER	BECKMAN COULTER	LH 750	FDA/CE	Coulter principle	BECKMAN COULTER	NA	FDA/CE	ABC Lab JHB	CAP	3 per yr	FH 6	Ļ
23	WBC Differential Count	COULTER	BECKMAN COULTER	LH 750	FDA/CE	VCS	BECKMAN COULTER	NA	FDA/CE	ABC Lab JHB	CAP	3 per yr	FH 6	L
24	Bacteriology							Without AC-						F
25	GC/CT	Probetec	BD	Probetec1 - PT- 2402 / Probetec- 2 - PT - 2167	Yes	SDA	BD	440705 ,With AC – 440450, Controls – 440451, Diluent –	Yes	XYZ Routine Lab	CAP	Thrice Annually	HC6	
26	Point of Care Testing													
27	BV Rapid	N/A	N/A	N/A	N/A	OSOM Rapid BV	OSOM/GRYPHUS	BVB25-1	Yes	XYZ Clinics	None	None	N/A	+
28	Trich Rapid	N/A	N/A	N/A	N/A	OSOM Rapid Trich	OSOM	181E	Yes	XYZ Clinics	CAP	Thrice Annually	VS1	4
29	KOH Wet Mount	N/A	N/A	N/A	N/A	Manual KOH preparation	N/A	N/A	N/A	XYZ Clinics	CAP	Thrice Annually	СММ	Ŧ



Proficiency Testing (EQA)



College of American Pathologists



Proficiency Testing (PT) is a means of evaluating a laboratory's performance through analysis of unknown samples provided by an external source.







EQA Summary Schedule

-	A	В	С	D	E	F	G	Н	I
1									
2									Investigation Report Required
3		2009				Lab Marris			Accutest#
4	-1	Ship	EQA	Cuprov	Module	Lab Name	SMILE Reviewed	Cito Deenenee	CAP#:
5			Provider	Survey Sequence	Code	Test Group Name	(Date)	Site Response (Date)	Comment
7	- 1	5-Jan	CAP	A	YM-1	Viral Markers	5-Mar-09	N/A	100% Successful
8	-	19-Jan	CAP	Ā	P	Parasitology	5-Mar-09	N/A	100% Successful
9	2	26-Jan	CAP	A	BP	Blood Parasites	1-Apr-09	8-May-09	Investigation required
	Ĩ	20-0an	001	~~~~~		Diood 1 araskes	FAP-00	011103-00	Investigation required for
	- 1								monocytes, neutrophils and
10	4	26-Jan	CAP	A	FH3	Hematology w/Auto Diff and Photos	1-Apr-09	30-Apr-09	blood cell ID.
11	5	9-Feb	CAP	A	E1	Limited Mycobacteriology	5-Jun-09	NłA	100% Successful
12	6	23-Feb	CAP	A	D5	Gram Stain	7-May-09	NłA	100% Successful
13	7	2-Mar	CAP	A	C3	General Chemistry	5-Jun-09	NłA	100% successful
14	8	16-Mar	CAP	A	СМ	Clinical Microscopy	7-May-09	N/A	100% Successful
15	9	30-Mar	CAP	A	D4	Bacteriology	5-Jun-09	N/A	100% Successful
16	- 10	30-Mar	CAP	A	ΑΗΙΥ	Raphid HIV-1/2	5-Jun-09	NłA	100% Successful
17	11	13-Apr	CAP	A	G	Syphilis Serology	5-Jun-09	NłA	100% Successful
18	12	4-May	CAP	В	FH3	Hematology w/Auto Diff and Photos	9-Jul-09	6-Aug-09	Investigation for Cell ID
19	3	4-May	CAP	в	Р	Parasitology	9-Jul-09	18-Aug-09	Investigation for Parasite ID and Photopages ID
20	4	11-May	CAP	В	VM-1	Viral Markers	9-Jul-09	NA	100% Successful
21	15	11-May	CAP	Α	XU6	Serum HCG	5-Jun-09	N/A	100% Successful
									Investigation received for Blood
22	6	18-May	CAP	В	BP	Blood Parasites	4-Aug-09	27-Aug-09	Parasite ID, accepted
23	7	1-Jun	Accutest	2	BACT435	Bacteriology	11-Sep-09	N/A	100% Successful
24	18	1-Jun	Accutest	2	GRAM435	Gram Stain	11-Sep-09		Investigation required for gram stain.
25	- 19	1-Jun	Accutest	2	HEFD435	Hematology	4-Aug-09	N/A	100% Successful
	_ L								
26	- 20	1-Jun	Accutest	2	CELL435	Blood Cell ID	4-Aug-09	08/27/09	Investigation received, accepted
27	1	1-Jun	Accutest	2	SHCG435	Serum HCG	4-Aug-09	N/A	100% Successful
28	22 23	1-Jun	Accutest	2	BCHE435	Chemistry	4-Aug-09	N/A	100% Successful
29	23 24	1-Jun	Accutest	2	HI¥435	Raphid HIV-1/2	4-Aug-09	N/A	100% Successful
30	24	1-Jun	Accutest CAP	B	SYPH435 C3	Syphilis Serology	4-Aug-09	N/A N/A	100% Successful 100% Successful
31 32	20	1-Jun 6-Jul	CAP	B	D5	General Chemistry Gram Stain	4-Aug-09 11-Sep-09	N/A N/A	100% Successful 100% Successful
32	27	3-Aug	CAP	B	CM	Clinical Microscopy	11-Sep-03	INFA	100% addeessful
33	28	3-Aug 3-Aug	CAP	B	E	Clinical Microscopy Mycobacteriology			
34	29	3-Aug 10-Aug	CAP	B	XS4	Serum HCG			
36	30	10-Aug	CAP	B		Baphid HIV-1/2			
36	1	10-Aug 10-Aug	CAP	B	D4	Bacteriology			
38	-	10-Aug	CAP	B	G	Syphilis Serology			
39	-#	24-Aug	CAP	c	VM-1	Viral Markers			
40	-	24-Aug 14-Sep	CAP	В	F1	Fungal			
40	Ŧ	21-Sep	CAP	c	FI FH3	Hematology w/Auto Diff and Photos			
42	-	21-Sep 21-Sep		č	BP	Blood Parasites			
42		Ziebep	CAP	0		Dioou Falasites			

	А	В	С	D	E	F	G	Н	1	J	K	L	М
1	Protocol/Non Proto	col Analytes: No Eve	nt or Not	Ordered									
		Result Not Submittee			uate								
		n (INT) Recommende											
		t Required (<100% bu		due within	n 30			Lab Nan	ne:	XYZ Lab			
		t (IR) Required (<80%						CAP# :					
	Non-protocol Analy		·					Accutes	#:				
	ACC - Acceptable												
8													
9				2007			2008			20	09		
10	Survey		A/1	B/2	C/3	A/1	B/2	C/3	A/1	В	2	C/3	
11	Chemistry	ALT				100%	100%	100%	100%	100%	100%		
12		Albumin				100%	100%	80%	100%	100%	100%		
13	Vitros 250	Alk Phos				100%	100%	100%	100%	100%	100%		
14		AST				100%	100%	100%	100%	100%	100%		
15		Bili, Direct				100%	100%	100%	100%	100%	100%		
16		Bili, Total				100%	100%	100%	100%	100%	100%		
17		Calcium				100%	100%	100%	100%	100%	100%		
18		Potassium - K				100%	100%	100%	100%	100%	100%		
19		Total Protein				100%	100%	100%	100%	100%	100%		
20		Sodium - Na				100%	60%	100%	100%	100%	100%		
21		Phosphorus				100%	100%	100%	100%	100%	100%		
22	Hematology	WBC	100%	100%	100%			100%	100%	100%	100%		
23		RBC	100%	100%	100%			100%	100%	100%	100%		
24	CellDyn3200	Hgb	100%	100%	100%			100%	100%	100%	100%		
25		Hct	100%	100%	100%			100%	100%	100%	100%		
26	Primary Instrument	MCV	100%	100%	100%			100%	100%	100%	100%		
27		RDW	100%	100%	100%			80%	100%	100%	100%		
28		Platelet	100%	100%	100%			60%	100%	100%	100%		
29		Neutrophil	100%	100%	100%			100%	80%	100%	100%		
30		Lymphs	100%	100%	100%			100%	100%	100%	100%		
31		Eos	80%	100%	100%			100%	100%	100%	100%		
32		Basos	100%	100%	100%			100%	100%	100%	100%		
33		Mono	100%	100%	100%			100%	80%	100%	100%		
34		Blood Cell ID				100%	78%	90%	90%	90%	80%		
35	Syphilis	MHA-TP	100%	100%	100%	100%	100%	100%	100%		100%		
36		RPR	100%	100%	80%	100%	100%	100%	100%		100%		
37		RPR Titer	100%	100%	80%	60%	100%	80%	100%				
38	GC-Chlamydia	Chlamydia	TNP	33%	66%								
39		GC	TNP	0%	100%								
40	HCG	Serum hCG (S)	100%	100%	100%		100%						
41		Serum hCG (XS-4)					100%	100%	100%		100%		
42	Anti-HIV	Method 1 (Abbott)	100%	100%	100%	100%	100%	100%	100%		100%		
43		Method 2 (Trinity)	100%	100%	40%	100%	100%	100%	100%		100%		
44	Viral Markers	HBsAg	100%	100%	100%	40%	100%	100%	100%	100%			
45		HRsAn Neutralz	100%	100%	100%	40%	100%	100%					
14 4	I 2009 Survey				lt Summary							- I 4 📖	
Rea	dy												

EQA Review

SMILE - EQA Evaluation

Date: 12 July 2011

EQA Provider: CAP#

Summary:

This EQA event was successful for all protocol analytes except as noted below.

A table containing manually evaluated results can be found on the following page.

Investigation Reports are required for all **protocol analytes** scoring less than 100%. The analytes requiring investigation are:

None

Internal investigations are recommended for non-protocol analytes scoring less than 100% and for any bias, shifts and/or trends identified below:

Bias noted Positive: None Negative: AST, Creatinine, Sodium

Shifts noted: NA

Trends noted: NA

Non-Protocol Analytes scoring less than 100%:

Sodium

Manual Evaluation

EVALUATION			VM-C 2010 Viral Markers				
ORIGINAL			VM-C 2010 VItal Markers				
Test	Specimen	Your Result	Intended Response	Your Grade			
Method HIV-1 WB Proteins	VM1-27	NO MAJOR PROT DETECTED	Intended Kesponse	[26]			
HIV-I wb Froteins	VM1-27	NO MAJOR PROT DETECTED		[20]			
	VM1-28	gp ⁴¹		[26]			
		P17/18					
		P ²⁴					
		p31/32					
		p51/55					
		P65/66					
		gp120/160					
	VM1-29	gp41 p17/18		[26]			
		p17/18 p24					
		p24 p31/32					
		p51/55					
		p65/66					
		gp120/160					
		SP-207 100					
	VM1-30	gp ⁴¹		[26]			
		P17/18					
		P ²⁴					
		P31/32					
		P51/55					
		P65/66					
		gp120/160					
	VM1-31	NO MAJOR PROT DETECTED		20			
	VM1-51	NO MAJOR I ROT DETECTED		[26]			

SMILE - Proficiency Evaluation

Date: 8 October 2010

Site:

Proficiency Provider: CAP #

Panel: Viral Markers VM-C, 2010

<u>~</u>⊗ ▲

Summary:

This EQA event was successful for all protocol analytes.

The table contains manually evaluated results.

SAMPLE	HIV-1 Wes	tern Blot		HIV-1 WE	B Proteins	
#	YOUR LAB RESULT	PEER RESULT	GRADE	YOUR LAB RESULT	PEER RESULT	GRADE
VM1-27	Negative	Negative	Acceptable	Not Detected	Not Detected	100%
VM1-28	Positive	Positive	Acceptable	gp41 p24 p31/32 p51/55 p65/66 gp120/160	gp41 p24 p31/32 p51/55 p65/66 gp120/160	100%
VM1-29	Positive	Positive	Acceptable	gp41 p24 p31/32 p51/55 p65/66 gp120/160	gp41 p24 p31/32 p51/55 p65/66 gp120/160	100%
VM1-30	Positive	Positive	Acceptable	gp41 p24 p31/32 p51/55 p65/66 gp120/160	gp41 p24 p31/32 p51/55 p65/66 gp120/160	100%
VM1-31	Negative	Negative	Acceptable	Not Detected	Not Detected	100%
					Average	100%

Investigation Reports are required for all **protocol analytes** scoring less than 100%. The <u>analytes</u> requiring investigation are:

None

Summary:

This EQA event was successful for all protocol analytes except as noted below. Since no method was chosen CAP did not grade the survey. SMILE manually graded the survey; see survey for results.

The table contains manually evaluated results.

SAMPLE #	YOUR LAB RESULT	PEER RESULT	GRADE		
CMMP-31	Sperm present	Sperm present	Acceptable		

Investigation Reports are required for all protocol analytes scoring less than 100%. The analytes requiring investigation are:

None

Internal investigations are recommended for the following non-protocol analytes scoring less than 100%:

- pH-33%
- Urobilinogen 66%

Comments:

Congratulations on your good EQA results.

Internal investigation is suggested for the pH and urobilinogen analytes.

On future surveys please enter the method code so CAP can grade the survey.

If you have any questions about your review please contact me.

Please remember to include both the method (Siemens) and instrument (Visual) on the next survey so CAP can grade this survey.

On the CAP instructions it specifies that when resulting of secondary confirmation methods (MHA-TP) where your process is to confirm only weakly reactive or reactive specimens that leaving presumed nonreactive specimens blank will results in a penalty. Please enter a code for your non-reactive test on your confirmatory test in the future.

SMILE Investigation Form

SMILE –Investigation Form							
Date: 12-Jan-09		Site:	ŀ				
Proficiency Provider & Panel: CAP C-C 2008							
Test Analyte (One/form if problems are unrelated):	Reported Result:	Acceptable Result:	Previous Survey Problems:				
Albumin	4.3	3.3 - 4.2	No				
Laboratory Investigation expand as needed.)	Laboratory Investigation: (Attach supporting documentation. Please add detailed comments. Comment section will expand as needed.)						
 Survey report examined for discrepancies, clerical errors and appropriate codes? Comments: NA 							
 Survey material receiving temperature, handling, reconstitution, storage and analysis investigated? Comments: Received warm 							
 Method & instrument history reviewed (Daily preventative maintenance performed? Reagents -open date, expiration date, number of tests left on the reagent, instrument settings, etc.)? Comments: Yes 							
 Quality Control reviewed (Circle or mark appropriate answer below.)? Yes 							
Mean established by? parallel to	esting or manufacturer's used	QC ranges are set? Manufac established	ture's range or locally				
QC within +/- 2 SD on day of sur	-	Number of levels of QC run?					
What QC rules do you use? 1_3	5	Does your laboratory track C analytes? CV = SD/Mean x 1	oefficient of Variation (CV) for 100 No				
Comments OC was within limits (slightly on the high side) but there was a humidity issue that has been resolved since							

Root cause analysis

SMILE -Investigation Form

9. Personnel competency reviewed? Conduct staff education or retraining if applicable. Comments: NA

10. Assess patient results for adverse impact? Review impacted patient results, amend results and notify physicians, if applicable. Comments: The Vitros 250 weren't used yet to assay patient results

Deficiency	Classification:
------------	-----------------

Methodological Technical

Clerical

Survey evaluation problem Other (explain)

Summary of Actions: Briefly discuss what actions were taken in this investigation and what you believe is the primary cause of this EQA problem.

The problem was caused by an influx of humidity in the slide reagent chamber due to screws that were not secured tightly enough


Summary of Actions: Briefly discuss what has been done to prevent this problem from occurring in the fature.

The problem was fixed and now the in case similar a problem in the future

) biomedical engineers will use this as a lesson

Prepared by:

Name/Title:



Document Repository

EQA surveys, reviews and investigations on www.psmile.org

- Available to site labs (privately by log-in)
- Available to DAIDS and the Networks

Where do we store all of this documentation?

Chttp://www.psmile.org/ - Windows Inte	ernet Explorer								
🕞 🕤 👻 🙋 http://www.psmile.org/		🔽 🐓 🗙 Google 🛛 🔎 🔹							
File Edit View Favorites Tools Help	🏟 Convert 👻 🔂 Select								
😪 🍄 🔏 http://www.psmile.org/		🟠 🔹 🔂 👻 🖶 🔹 🎲 Page 🔹 🎯 Tools 🔹							
	Home About pSmile Site Labs Resources People Organizations Contact Us	© New User							
		-							
Quick Links	Welcome to Project pSMILE!								
EQA Providers- Protocol Preferred	This web site is operated by the Johns Hopkins University for the pSMILE project (Patient Safety Monitoring & International Laboratory Evaluation) sponsored by the National Institutions of Health (NIH) Division of AIDS (DAIDS) under contract HHSN 266 2005 000 IC Miller (PI) 11/16/04-11/15/11.								
EQA Providers_Non-Protocol Rapid HIV Testing Provider	The Resource section of pSMILE has been reorganized! Resources are now categorized by topic and the search capabilities have been expanded to make it								
Network Protocol Analytes - 24Sep2007	easier for you to find what you need.								
 SMILE-PNL Investigation Form V4.0 SMILE-PNL Investigation Form for 	Where applicable, documents and links have references to the PPD audit within the description area. If you have any problems or questions, please contact your SMILE representative or use the Contact Us tab for your inquiries.								
Microbiology V4.0	Please click here to request access to this web site.								
Home About pSmile Site Labs Resources People Organizations Contact Us									

2005 - 2009 Johns Hopkins University. All Rights Reserved

Disclaimer | Privacy Policy

Site Visits: 95681



Logout

Hello, asholan

	Home	About pSmile	Site Labs	Documents	Resources	People	Organizations	Conta		
Quick Links	Do	ocuments 2009								
EQA Providers- Protocol	Group -	Group - All sites								
Preferred EQA Providers_Non-Protocol Rapid HIV Testing Provider Network Protocol Analytes -										
	Μοι	Mouse-over icon for details Click icon to download Click here to Upload								
24Sep2007 ▲ Ø SMILE-PNL Investigation Form		Selec	ct Year 2005	2006 2007 2008	2009					
V4.0 ▲ SMILE-PNL Investigation Form for	,	Proficiency Testing Records								
Microbiology V4.0 ▲ Laboratory Mnemonic List ▲		ıto Dermatologico								
SMILE Laboratory Oversight List SMILE Weekly EQA Review Schedule	X	IDCP EQA Summa	[Update]							
		IDCP CAP2009 Cli	[Update]							
		DCP CAP2009 Clinical Microscopy CM-B Survey 10/03/2009								
		IDCP CAP2009 Ch	08/04/2009	[Update]						
		IDCP CAP2009 Ch	emistry C-B S	urvey	08/03/2009	[Update]				
		IDCP CAP2009 Vi	ral Markers VI	M-B Review	08/02/2009	[Update]				
		IDCP CAP2009 Vi	ral Markers VI	M-B Survey	08/01/2009	[Update]				
		IDCP CAP2009 He	matology FH3	-B Investigation	06/28/2009	[Update]				
		IDCP CAP2009 He	matology FH3	-B Review	06/28/2009	[Update]				
		IDCP CAP2009 He	matology FH3	-B Survey	06/27/2009	[Update]				
	W	IDCP CAP2009 Ch	emistry C-A R	eview	05/30/2009	[Update]				

Document Repository

Also on www.psmile.org:

- Audits (DAIDS and PPD)
- Action Plans
- Protocols and Protocol Analyte Lists (PAL)
- Multitudes of other resources

Looking for example SOPs or other documentation?

//www.psmile.org/ - Windows Inte	rnet Explorer								_ 8 ×
🚱 🕤 👻 🙋 http://www.psmile.org/								Google 🗲 🖌	₽ •
File Edit View Favorites Tools Help		🍖 Convert	👻 🛃 Select						
😪 🍄 🔏 http://www.psmile.org/								🟠 • 🗟 - 🖶	🕶 🔂 Page 👻 🎯 Tools 👻 🂙
			nt Safety Monito	toring & International L				◎ New User	
l L	Home	About pSmile	Site Labs	Resources	People	Organizations	Contact Us		
Quick Links EQA Providers- Protocol Preferred EQA Providers_Non-Protocol Rapid HIV Testing Provider Network Protocol Analytes - 24Sep2007 SMILE-PNL Investigation Form V4.0 SMILE-PNL Investigation Form for Microbiology V4.0	This web sit National Ins The Resource easier for your of the second sec	stitutions of Health (rce section of pSMIL you to find what you licable, documents a	e Johns Hopkir (NIH) Division o LE has been red need. and links have he <u>Contact Us</u> to	of AIDS (DAIDS) under corganized! Resources references to the PPI tab for your inquiries.	er contract HHSI es are now cate PD audit within t	SN 266 2005 000 IC I	Miller (PI) 11/16/	tional Laboratory Evaluation) sponsored by t //04-11/15/11. pabilities have been expanded to make it ny problems or questions, please contact yo	
Home About pSmile Site Labs Resources People Organizations Contact Us									
© 2005 - 2009 Johns Hopkins University. All Rights Reserved.									

Disclaimer | Privacy Policy

Site Visits: 95681

Resources on pSMILE.org

Address 🙋 http://resources.psmile	s.org/resources	💌 🄁 Go 🛛 Links 🍟 🍕 🗸			
Home Resources	onitoring & International Laboratory Evaluation	Site Map Accessibility Contact			
You are here: Home → Res	ources	Water Quality [100%]			
Disclaimer	Resources	PPD Audit Reference: Test and Control Articles Water Quality SOP [98%] PPD Audit Reference: Test and Control Articles SOP Checklist - Water Quality [97%]			
This page is in development. All documents are	Accreditation and Assessment	PPD Audit reference: Testing Facilities Operation Giemsa stain Quality Control [96%] PPD Audit reference: Test and Control Articles			
intended as examples and may be freely	Customer Service	Section Wright's Stain (Diff Quick) M [92%]			
distributed. We welcome suggestions,	Documents and Records	PPD Audit reference: Equipment Section Troemner Pipette Standards Ha [92%] PPD Audit reference: Equipment Section			
comments, and items for submission. Please	🗅 Equipment	Cobas Integra 400 Troubleshoo [91%] PPD Audit reference: Equipment Section Chemistry-Intergra400plus- 0p [91%]			
contact us at smile@jhmi.edu.	🗅 <u>Facilities & Safety</u>	PPD Audit reference: Equipment Section Pipette Calibration SOP [90%]			
Quick Links	Information Management	PPD Audit reference: Equipment Section Gram Stain SOP [90%] PPD Audit reference: Test and Control Articles			
About pSMILE Site Labs	Dccurrence Management	Section Advanced Search Show all			
People Organizations Contact Us	Organization				
Plone Help	Personnel Processes Process Control				



Competency Tests for your facility specific procedures

Streamline your PPMP Competency Assessment process: an online program for administering and tracking tests that actually works!

TRAINING

MTS training courses teach staff and students essential laboratory skills. Clinical laboratories and MT/MLT programs use the training library for:

- Initial Training for staff and students
- Continuing Education (P.A.C.E., CA, FL)
- Cross training lab personnel
- Reference and remediation
- Patient safety training

Learn more

COMPETENCY ASSESSMENT

Bi-annual objective tests cover pre-analytic, core lab, waived testing, PPMP, and instrument competencies. Tracking and documentation tools help fulfill regulatory requirements and make administration easy.

- Automated e-mail notification for participants
- High-resolution photos and slide images
- In-depth explanations for remediation
- Summary reports for managers
- Create your own custom tests

Learn more



www.medtraining.org

Contact Terms of Use & Privacy Policy © Copyright 2004, Medical Training Solutions, Inc. All Rights Reserved.

SMILE Site Assistance and Training

- Email
- Phone
- Web conference
 Adobe Connect
- At conferences
- On site



Major Functions of SMILE

Action Plans

- Validation Review
- Protocol Analyte Lists
 - EQA Review
 - Investigations
 - Resources/Training





Anne Sholander: asholan2@jhmi.edu

Mark Swartz: mswartz4@jhmi.edu